ranolazine has been researched along with natriuretic peptide, brain in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, C; Braunwald, E; de Lemos, JA; Jarolim, P; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Theroux, P | 1 |
| Califf, RM; Newby, LK; Shah, SH | 1 |
| Belardinelli, L; Hasenfuss, G; Jacobshagen, C; Maier, LS | 1 |
| Bonaca, MP; Braunwald, E; Kakkar, R; Kohli, P; Kudinova, AY; Lee, RT; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM | 1 |
| Henderson, RA; Timmis, AD | 1 |
| Arcari, A; Arra, C; Campesan, M; Carpi, A; Cipresso, C; Condorelli, G; Coppola, C; De Lorenzo, C; Di Lisa, F; Maurea, N; Monti, MG; Piscopo, G; Quintavalle, C; Rea, D; Tocchetti, CG | 1 |
1 review(s) available for ranolazine and natriuretic peptide, brain
| Article | Year |
|---|---|
[Almanac 2011: Stable coronary artery disease. An editorial overview of selected research that has driven recent advances in clinical cardiology].
Topics: Acetanilides; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Benzazepines; Biomarkers; Cardiology; Coronary Artery Bypass; Coronary Artery Disease; Drug-Eluting Stents; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Ivabradine; Natriuretic Agents; Natriuretic Peptide, Brain; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
2 trial(s) available for ranolazine and natriuretic peptide, brain
| Article | Year |
|---|---|
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thr
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Biomarkers; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Ranolazine; Risk Factors | 2010 |
Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
Topics: Acetanilides; Administration, Oral; Biomarkers; Cardiac Catheterization; Cardiovascular Agents; Double-Blind Method; Echocardiography, Doppler; Germany; Heart Failure, Diastolic; Humans; Infusions, Intravenous; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Piperazines; Placebo Effect; Prospective Studies; Ranolazine; Recovery of Function; Research Design; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Pressure | 2011 |
3 other study(ies) available for ranolazine and natriuretic peptide, brain
| Article | Year |
|---|---|
Biomarker bonanza?
Topics: Acetanilides; Acute Coronary Syndrome; Biomarkers; Enzyme Inhibitors; Humans; Natriuretic Peptide, Brain; Piperazines; Ranolazine; Risk Factors | 2010 |
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Biomarkers; Cardiovascular Diseases; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Male; Natriuretic Peptide, Brain; Piperazines; Prognosis; Randomized Controlled Trials as Topic; Ranolazine; Receptors, Cell Surface; Risk Assessment | 2012 |
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
Topics: Acetanilides; Animals; Antibiotics, Antineoplastic; Atrial Natriuretic Factor; Blotting, Western; Cardiotoxicity; Connective Tissue Growth Factor; Doxorubicin; Enzyme Inhibitors; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Oxidative Stress; Piperazines; Poly(ADP-ribose) Polymerases; Ranolazine; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Ultrasonography; Ventricular Dysfunction, Left | 2014 |